4 results on '"Walla, B."'
Search Results
2. Efficacy of oral versus long-acting antipsychotic treatment in patients with early-phase schizophrenia in Europe and Israel: a large-scale, open-label, randomised trial (EULAST)
- Author
-
Inge Winter-van Rossum, Mark Weiser, Silvana Galderisi, Stefan Leucht, Istvan Bitter, Birte Glenthøj, Alkomiet Hasan, Jurjen Luykx, Marina Kupchik, Georg Psota, Paola Rocca, Nikos Stefanis, Alexander Teitelbaum, Mor Bar Haim, Claudia Leucht, Georg Kemmler, Timo Schurr, Michael Davidson, René S Kahn, W Wolfgang Fleischhacker, René Sylvain Kahn, Walter Wolfgang Fleischhacker, Monica Mosescu, George Umoh, Lucho Hranov, Alex Hofer, Joachim Cordes, Ramin Nilforooshan, Julio Bobes, Solveig Klebo Reitan, Manuel Morrens, Aurel Nirestean, John Geddes, Benedicto Crespo Faccorro, Marcin Olajossy, Alessandro Rossi, Erik Johnsen, Csekey László, Adela Ciobanu, Peter Haddad, Igor Oife, Miquel Bernardo, Rodicutza Stan, Marek Jarema, Dan Rujescu, Libor Ustohal, Neil Mayfield, Paola Dazzan, Avi Valevski, Jan Libiger, Richard Köhler, Pavel Mohr, Sofia Pappa, Petros Drosos, Thomas Barnes, Esther DeClercq, Elias Wagner, Paola Bucci, Armida Mucci, Yaacov Rabinowitz, Adam Adamopoulous, Benjamin Draiman, Cristiana Montemagni, Manfred Greslechner, Hannah Herlihy, Csilla Bolyos, Christian Schmidt-Kraepelin, Jessica TRUE, Leticia Alvarez Garcia, Berit Walla, Bernhard Sabbe, Lucaks Emese, Sarah Mather, Nikodem Skoczen, Serena Parnanzone, Jill Bjarke, Krisztina Karácsonyi, Steve Lankshear, Marina Garriga, Adam Wichniak, Heidi Baumbach, Leonie Willebrands, Lyliana Nasib, Cynthia Okhuijsen-Pfeifer, Elianne Huijsman, Winter-van Rossum, I., Weiser, M., Galderisi, S., Leucht, S., Bitter, I., Glenthoj, B., Hasan, A., Luykx, J., Kupchik, M., Psota, G., Rocca, P., Stefanis, N., Teitelbaum, A., Bar Haim, M., Leucht, C., Kemmler, G., Schurr, T., Kahn, R. S., Fleischhacker, W. W., Davidson, M., Mosescu, M., Umoh, G., Hranov, L., Hofer, A., Cordes, J., Nilforooshan, R., Bobes, J., Reitan, S. K., Morrens, M., Nirestean, A., Geddes, J., Crespo Faccorro, B., Olajossy, M., Rossi, A., Johnsen, E., Laszlo, C., Ciobanu, A., Haddad, P., Oife, I., Bernardo, M., Stan, R., Jarema, M., Rujescu, D., Ustohal, L., Mayfield, N., Dazzan, P., Valevski, A., Libiger, J., Kohler, R., Mohr, P., Pappa, S., Drosos, P., Barnes, T., Declercq, E., Wagner, E., Bucci, P., Mucci, A., Rabinowitz, Y., Adamopoulous, A., Draiman, B., Montemagni, C., Greslechner, M., Herlihy, H., Bolyos, C., Kraepelin-Schmidt, C., True, J., Alvarez Garcia, L., Walla, B., Sabbe, B., Emese, L., Mather, S., Skoczen, N., Parnanzone, S., Bjarke, J., Karacsonyi, K., Lankshear, S., Garriga, M., Wichniak, A., Baumbach, H., Willebrands, L., Nasib, L., Okhuijsen-Pfeifer, C., and Huijsman, E.
- Subjects
Psychiatry and Mental health ,1ST-EPISODE SCHIZOPHRENIA ,RISPERIDONE ,DRUGS ,TOLERABILITY ,ddc:610 ,MAINTENANCE TREATMENT ,RELAPSE ,Biological Psychiatry - Abstract
Background: Schizophrenia is a severe psychiatric disorder with periods of remission and relapse. As discontinuation of antipsychotic medication is the most important reason for relapse, long-term maintenance treatment is key. Whether intramuscular long-acting (depot) antipsychotics are more efficacious than oral medication in preventing medication discontinuation is still unresolved. We aimed to compare time to all-cause discontinuation in patients randomly allocated to long-acting injectable (LAI) versus oral medication. Methods: EULAST was a pragmatic, randomised, open-label trial conducted at 50 general hospitals and psychiatric specialty clinics in 15 European countries and Israel. Patients aged 18 years and older, with DSM-IV schizophrenia (as confirmed by the Mini International Neuropsychiatric Interview 5 plus) and having experienced their first psychotic episode from 6 months to 7 years before screening, were randomly allocated (1:1:1:1) using block randomisation to LAI paliperidone, LAI aripiprazole, or the respective oral formulations of these antipsychotics. Randomisation was stratified by country and duration of illness (6 months up to 3 years vs 4 to 7 years). Patients were followed up for up to 19 months. The primary endpoint was discontinuation, regardless of the reason, during 19 months of treatment. We used survival analysis to assess the time until all-cause discontinuation in the intention-to-treat (ITT) group, and per protocol analyses were also done. This trial is registered with ClinicalTrials.gov, NCT02146547, and is complete. Findings: Between Feb 24, 2015, and Dec 15, 2018, 533 individuals were recruited and assessed for eligibility. The ITT population included 511 participants, with 171 (33%) women and 340 (67%) men, and a mean age of 30·5 (SD 9·6) years. 410 (80%) of 511 participants were White, 35 (7%) were Black, 20 (4%) were Asian, and 46 (9%) were other ethnicity. In the combined oral antipsychotics treatment group of 247 patients, 72 (29%) patients completed the study and 175 (71%) met all-cause discontinuation criteria. In the combined LAI treatment arm of 264 patients, 95 (36%) completed the study and 169 (64%) met the all-cause discontinuation criteria. Cox regression analyses showed that treatment discontinuation for any cause did not differ between the two combined treatment groups (hazard ration [HR] 1·16, 95% CI 0·94–1·43, p=0·18). No significant difference was found in the time to all-cause discontinuation between the combined oral and combined LAI treatment groups (log rank test χ 2=1·87 [df 1]; p=0·17). During the study, 121 psychiatric hospitalisations occurred in 103 patients, and one patient from each of the LAI groups died; the death of the patient assigned to paliperidone was assessed to be unrelated to the medication, but the cause of other patient's death was not shared with the study team. 86 (25%) of 350 participants with available data met akathisia criteria and 70 (20%) met parkinsonism criteria at some point during the study. Interpretation: We found no substantial advantage for LAI antipsychotic treatment over oral treatment regarding time to discontinuation in patients with early-phase schizophrenia, indicating that there is no reason to prescribe LAIs instead of oral antipsychotics if the goal is to prevent discontinuation of antipsychotic medication in daily clinical practice. Funding: Lundbeck and Otsuka.
- Published
- 2023
3. Spectroscopic insights into multi-phase protein crystallization in complex lysate using Raman spectroscopy and a particle-free bypass.
- Author
-
Wegner CH, Eming SM, Walla B, Bischoff D, Weuster-Botz D, and Hubbuch J
- Abstract
Protein crystallization as opposed to well-established chromatography processes has the benefits to reduce production costs while reaching a comparable high purity. However, monitoring crystallization processes remains a challenge as the produced crystals may interfere with analytical measurements. Especially for capturing proteins from complex feedstock containing various impurities, establishing reliable process analytical technology (PAT) to monitor protein crystallization processes can be complicated. In heterogeneous mixtures, important product characteristics can be found by multivariate analysis and chemometrics, thus contributing to the development of a thorough process understanding. In this project, an analytical set-up is established combining offline analytics, on-line ultraviolet visible light (UV/Vis) spectroscopy, and in-line Raman spectroscopy to monitor a stirred-batch crystallization process with multiple phases and species being present. As an example process, the enzyme Lactobacillus kefir alcohol dehydrogenase (L k ADH) was crystallized from clarified Escherichia coli ( E. coli ) lysate on a 300 mL scale in five distinct experiments, with the experimental conditions changing in terms of the initial lysate solution preparation method and precipitant concentration. Since UV/Vis spectroscopy is sensitive to particles, a cross-flow filtration (cross-flow filtration)-based bypass enabled the on-line analysis of the liquid phase providing information on the lysate composition regarding the nucleic acid to protein ratio. A principal component analysis (PCA) of in situ Raman spectra supported the identification of spectra and wavenumber ranges associated with productspecific information and revealed that the experiments followed a comparable, spectral trend when crystals were present. Based on preprocessed Raman spectra, a partial least squares (PLS) regression model was optimized to monitor the target molecule concentration in real-time. The off-line sample analysis provided information on the crystal number and crystal geometry by automated image analysis as well as the concentration of Lk ADH and host cell proteins (HCPs) In spite of a complex lysate suspension containing scattering crystals and various impurities, it was possible to monitor the target molecule concentration in a heterogeneous, multi-phase process using spectroscopic methods. With the presented analytical set-up of off-line, particle-sensitive on-line, and in-line analyzers, a crystallization capture process can be characterized better in terms of the geometry, yield, and purity of the crystals., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2024 Wegner, Eming, Walla, Bischoff, Weuster-Botz and Hubbuch.)
- Published
- 2024
- Full Text
- View/download PDF
4. Machine learning-based protein crystal detection for monitoring of crystallization processes enabled with large-scale synthetic data sets of photorealistic images.
- Author
-
Bischoff D, Walla B, and Weuster-Botz D
- Subjects
- Algorithms, Crystallization, Image Processing, Computer-Assisted methods, Proteins, Machine Learning, Neural Networks, Computer
- Abstract
Since preparative chromatography is a sustainability challenge due to large amounts of consumables used in downstream processing of biomolecules, protein crystallization offers a promising alternative as a purification method. While the limited crystallizability of proteins often restricts a broad application of crystallization as a purification method, advances in molecular biology, as well as computational methods are pushing the applicability towards integration in biotechnological downstream processes. However, in industrial and academic settings, monitoring protein crystallization processes non-invasively by microscopic photography and automated image evaluation remains a challenging problem. Recently, the identification of single crystal objects using deep learning has been the subject of increased attention for various model systems. However, the advancement of crystal detection using deep learning for biotechnological applications is limited: robust models obtained through supervised machine learning tasks require large-scale and high-quality data sets usually obtained in large projects through extensive manual labeling, an approach that is highly error-prone for dense systems of transparent crystals. For the first time, recent trends involving the use of synthetic data sets for supervised learning are transferred, thus generating photorealistic images of virtual protein crystals in suspension (PCS) through the use of ray tracing algorithms, accompanied by specialized data augmentations modelling experimental noise. Further, it is demonstrated that state-of-the-art models trained with the large-scale synthetic PCS data set outperform similar fine-tuned models based on the average precision metric on a validation data set, followed by experimental validation using high-resolution photomicrographs from stirred tank protein crystallization processes., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.